DEI is under attack—watered down, defunded, and dismissed. But let’s be clear: its death is neither inevitable nor acceptable. In this episode of No Ordinary Subjects, I confront the backlash against diversity, equity, and inclusion head-on, exposing the paranoid hypocrisy of those who claim DEI has "gone too far" while systemic inequities remain as stark as ever. I call out the performative gestures and demand accountability. From empty corporate pledges to outright rollbacks, I call out the administration for fueling this backlash with their paranoid, regressive narrative. DEI isn’t a trend—it’s a fixture, no matter what you want to call it. Because on my watch, silence is not an option.
#ClinicalTrials #HealthEquity #DiversityInResearch #UnderrepresentedCommunities #ClinicalResearch #Biopharma #RegulatoryAgencies #CROs #PatientAdvocacy #HealthInnovation #NoOrdinarySubjects #Podcast #HealthPodcast #MedicalResearch #ClinicalResearch #InclusionInResearch #HealthDisparities #PrecisionMedicine #PersonalizedMedicine #PatientCentricity #ResearchEthics #FDA #NIH #EquityInHealth #ChangeTheStatusQuo #MeaningfulSolutions #DEIinHealthcare #HealthDisparities #InclusionInResearch #PatientAdvocacy #PatientStories #HealthPolicy #HealthInnovation #Biotech #Pharmaceuticals #MedicalPodcast #EquityInHealth #RepresentationMatters #UnconsciousBias #CulturalCompetency #HealthJustice #ResearchEthics #UnderrepresentedCommunities #HealthOutcomes #ClinicalCare #HealthResearch
